WO2009120657A3 - Anticorps monoclonaux humains dirigés contre la protéine bêta-amyloïde, et leur utilisation en tant qu'agents thérapeutiques - Google Patents

Anticorps monoclonaux humains dirigés contre la protéine bêta-amyloïde, et leur utilisation en tant qu'agents thérapeutiques Download PDF

Info

Publication number
WO2009120657A3
WO2009120657A3 PCT/US2009/038027 US2009038027W WO2009120657A3 WO 2009120657 A3 WO2009120657 A3 WO 2009120657A3 US 2009038027 W US2009038027 W US 2009038027W WO 2009120657 A3 WO2009120657 A3 WO 2009120657A3
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibodies
therapeutic agents
antibodies against
human monoclonal
amyloid beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/038027
Other languages
English (en)
Other versions
WO2009120657A2 (fr
Inventor
Moses Rodriguez
Larry R. Pease
Arthur E. Warrington, Jr.
Nilufer Taner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Foundation for Medical Education and Research
Mayo Clinic in Florida
Original Assignee
Mayo Foundation for Medical Education and Research
Mayo Clinic in Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation for Medical Education and Research, Mayo Clinic in Florida filed Critical Mayo Foundation for Medical Education and Research
Publication of WO2009120657A2 publication Critical patent/WO2009120657A2/fr
Publication of WO2009120657A3 publication Critical patent/WO2009120657A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention porte sur des matériels et des procédés pour identifier des auto-anticorps anti-Aβ naturels humains, ainsi que sur des matériels et des procédés permettant d’utiliser de tels anticorps pour traiter la maladie d'Alzheimer.
PCT/US2009/038027 2008-03-26 2009-03-24 Anticorps monoclonaux humains dirigés contre la protéine bêta-amyloïde, et leur utilisation en tant qu'agents thérapeutiques Ceased WO2009120657A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3960308P 2008-03-26 2008-03-26
US61/039,603 2008-03-26

Publications (2)

Publication Number Publication Date
WO2009120657A2 WO2009120657A2 (fr) 2009-10-01
WO2009120657A3 true WO2009120657A3 (fr) 2009-12-17

Family

ID=41114624

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/038027 Ceased WO2009120657A2 (fr) 2008-03-26 2009-03-24 Anticorps monoclonaux humains dirigés contre la protéine bêta-amyloïde, et leur utilisation en tant qu'agents thérapeutiques

Country Status (1)

Country Link
WO (1) WO2009120657A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030185827A1 (en) * 1994-04-29 2003-10-02 Mayo Foundation Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030185827A1 (en) * 1994-04-29 2003-10-02 Mayo Foundation Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GEYLIS V. ET AL.: "Human monoclonal antibodies against amyloid-beta from healthy adults", NEUROBIOL. AGING, vol. 26, no. 5, May 2005 (2005-05-01), pages 597 - 606 *
GEYLIS V. ET AL.: "Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies", AUTOIMMUN. REV., vol. 5, no. 1, January 2006 (2006-01-01), pages 33 - 39 *
HOEW, C. L. ET AL.: "Antiapoptotic signaling by a remyelination-promoting human antimyelin antibody", NEUROBIOL. DIS., vol. 15, no. 1, February 2004 (2004-02-01), pages 120 - 131 *
WARRINGTON A. E. ET AL.: "Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis", PROC. NATL. ACAD. SCI. U S A, vol. 97, no. 12, 6 June 2000 (2000-06-06), pages 6820 - 6825 *

Also Published As

Publication number Publication date
WO2009120657A2 (fr) 2009-10-01

Similar Documents

Publication Publication Date Title
AU2018256498A1 (en) Antibodies to amyloid beta
UA109633C2 (uk) Антитіло людини проти тканинного фактора
EA201270813A1 (ru) АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ
CY1115906T1 (el) Ανθρωποποιημενα αντισωματα κατα του βητα αμυλοειδους
MY164376A (en) Phosphospecific antibodies recognizing tau
EA201000644A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
EA201171388A1 (ru) Гуманизированные антитела, специфичные к протофибриллярной форме бета-амилоидного пептида
WO2009048538A3 (fr) Anticorps humanisé
NO20090156L (no) Humanisert antistoff
WO2009149486A3 (fr) Composés destinés au traitement de maladies
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
MX354662B (es) Anticuerpos fosfoespecificos que reconocen la tau.
MX356800B (es) Anticuerpo tau humanizado.
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
WO2009048539A3 (fr) Anticorps monoclonal
MX341369B (es) Anticuerpo anti-beta-amiloide humanizado seguro y funcional.
UA107490C2 (uk) TNF-α-ЗВ'ЯЗУВАЛЬНИЙ БІЛОК
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
UA101167C2 (ru) Фармацевтическая композиция, предназначенная для лечения глазной болезни
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
WO2008122441A3 (fr) Anticorps anti-amyloïdes et leur utilisation pour le diagnostic et le traitement de maladies amyloïdes
CY2022028I2 (el) Εξανθρωπισμενα αντισωματα αντι-cd19 και οι χρησεις τους στην θεραπεια ογκων, μεταμοσχευσης και ασθενειων αυτο-ανοσιας
WO2012021475A3 (fr) ANTICORPS CONTRE LE PEPTIDE N3pGLU AMYLOÏDE BÊTA ET LEURS UTILISATIONS
PH12012501743A1 (en) Antigen binding proteins specific for serum amyloid p component
CY1114604T1 (el) Ανθρωποποιημενο αντισωμα εναντιον αμυλοειδους βητα

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09725118

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09725118

Country of ref document: EP

Kind code of ref document: A2